請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/15659完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 陳基旺 | - |
| dc.contributor.author | Chen-Wei Huang | en |
| dc.contributor.author | 黃振瑋 | zh_TW |
| dc.date.accessioned | 2021-06-07T17:49:34Z | - |
| dc.date.copyright | 2013-03-04 | - |
| dc.date.issued | 2013 | - |
| dc.date.submitted | 2013-01-31 | - |
| dc.identifier.citation | 1.5 References
1. Cummings, J. L. and Zhong, K. Treatments for behavioural disorders in neurodegenerative diseases: drug development strategies. Nat. Rev. drug discov. 2006, 5, 64-74. 2. Campbell, A. Inflammation, Neurodegenerative diseases, and environmental exposures. Ann. N.Y. Acad. Sci. 2004, 1035, 117-132. 3. Coppede`, F.; Mancuso, M.; Siciliano, G.; Migliore, L.; Murri, L. Genes and the Environment in neurodegeneration. Biosci. Rep. 2006, 26, 341-367. 4. Coppede`, F. and Migliore, L. Environmental-induced oxidative stress in neurodegenerative disorders and aging. Mutat. Res. 2009, 674, 73-84. 5. Andersen, J. K. Oxidative stress in neurodegeneration: cause or consequence. Nat. Rev. Neurosci. 2004, 5, S18-S25. 6. Ross, C. A. and Poirier, M. A. Protein aggregation and neurodegenerative disease. Nat. Med. 2004, 10, S10-S17. 7. Soto, C. and Estrada, L. D. Protein misfolding and neurodegeneration. Arch Neurol. 2008, 65, 184-189. 8. Bartolini, M. and Andrisano, V. Strategies for the inhibition of protein aggregation in human diseases. ChemBioChem 2010, 11, 1018-1035. 9. Alzheimer’s disease international. World Alzheimer report 2009. 10. Bartus, R. T.; Dean III, R. L.; Beer, B.; Lippa, A. S. The Cholinergic hypothesis of geriatric memory dysfunction. Science 1982, 217, 408-414. 11. Hardy, J. A. and Higgins, G. A. Alzheimer's Disease: The Amyloid cascade hypothesis. Science 1992, 256, 184-185. 12. Lovell, M. A.; Robertson, J. D.; Teesdale, W. J.; Campbell, J. L.; Markesbery, W. R. Copper, iron and zinc in Alzheimer’s disease senile plaques. J. Neurol. Sci. 1998, 158, 47-52. 13. Allsop, D.; Mayes, J.; Moore, S.; Masad, A.; Tabner, B. J. Metal-dependent generation of reactive oxygen species from amyloidal proteins implicated in neurodegenerative disease. Biochem. Soc. Trans. 2008, 36, 1293-1298. 14. Bush, A. I.; Pettingell, W. H.; Multhaup, G.; Paradis, M. d.; Vonsattel, J. P.; Gusella, J. F.; Beyreuther, K.; Masters, C. L.; Tanz, R. E. Rapid induction of Alzheimer Aβ amyloidal formation by zinc. Science 1994, 265, 1464-1467. 15. Reinke, A. A.; Gestwicki, J. E. Structure–activity relationships of amyloidal beta-aggregation inhibitors based on curcumin: influence of linker length and flexibility. Chem. Biol. Drug Des. 2007, 70, 206-215. 16. Porat, Y.; Abramowitz, A.; Gazit, E. Inhibition of amyloidal fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism Chem. Biol. Drug Des. 2006, 67, 27-37. 17. Necula, M.; Kayed, R.; Milton, S.; Glabe, C. G. Small Molecule Inhibitors of Aggregation Indicate That Amyloid Oligomerization and Fibrillization Pathways Are Independent and Distinct. J. Biol. Chem. 2007, 282, 10311-10324. 18. Dolai, S.; Shi, W.; Corbo, C.; Sun, C.; Averick, S.; Obeysekera, D.; Farid, M.; Alonso, A.; Banerjee, P.; Raja, K. “Clicked” sugar-curcumin conjugate: modulator of amyloidal-β and tau peptide aggregation at ultralow concentration. ACS Chem. Neurosci. 2011, 2, 694-699. 19. Levine III, H. Quantification of β-sheet amyloidal fibril structures with thioflavin T. Meth. Enzymol. 1999, 309, 274. 20. Lorenzo, A.; Yankner, B. A.; β-Amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc. Natl. Acad. Sci. USA. 1994, 91, 12243-12247. 21. Klunk, W. E.; Debnath, M. L.; Koros, A. M. C.; Pettegrew, J. W. Chrysamine-G, a lipophilic analogue of Congo red, inhibits Aβ-induced toxicity in PC12 cells. LIFE SCI. 1998, 63, 1807-1814. 22. Simons, L. J.; Caprathe, B. W.; Callahan, M.; Graham, J. M.; Kimura, T.; Lai, Y. J.; LeVine III, H.; Lipinski, W.; Sakkab, A. T.; Tasaki, Y.; Walker, L. C.; Yasunaga, T.; Ye, Y. Y.; Zhuang, N.; Augelli-Szafran, C. E.; The synthesis and structure-activity relationship of substituted N-phenyl anthranilic acid analogs as amyloidal aggregation inhibitors. Bioorg. Med. Chem. Lett. 2009, 19, 654-657. 23. Mathis, C. A.; Wang, Y. M.; Holt, D. P.; Huang, G. F.; Debnath, M. L.; Klunk, W. E. Synthesis and Evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloidal imaging agents. J. Med. Chem. 2003, 46, 2740-2754. 24. Chen, J.; Armstrong, A. H.; Koehler, A. N.; Hecht, M. H. Small molecule microarrays enable the discovery of compounds that bind the Alzheimer’s Aβ peptide and reduce its cytotoxicity. J. Am. Chem. Soc. 2010, 132, 17015-17022. 25. Cavalli, A.; Bolognesi, M. L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Recanatini, M.; Melchiorre, C. Multi-target-directed Ligands to combat neurodegenerative Diseases. J. Med. Chem. 2008, 51, 347-372. 26. Leo’n, R.; Garcia, A. G.; Marco-Contelles, J. Recent advances in the Multitarget-directed ligands approach for the treatment of Alzheimer’s disease. Med. Res. Rev. 2011, 31, 1-51 27. Dedeoglu, A.; Cormier, K.; Payton, S.; Tseitlin, K. A.; Kremsky, J. N.; Lai, L.; Xiaohua Li, X. H.; Moir, R. D.; Tanzi, R. E.; Bush, A. I.; Kowall, N. W.; Jack T. Rogers, J. T.; Huang, X. D. Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer’s amyloidogenesis. Exp. Gerontol. 2004, 39, 1641-1649. 28. Zhang, Y.; Chen, L. Y.; Yin, W. X.; Yin, J.; Zhang, S. B.; Liu, C. L.; The chelation targeting metal-Aβ40 aggregates may lead to formation of Aβ40 oligomers. Dalton Trans. 2011, 40, 4830-4833. 29. Sharma, A. K.; Pavlova, S. T.; Kim, J. W.; Finkelstein, D.; Hawco, N. J.; Rath, N. P.; Kim, J. S.; Mirica, L. M. Bifunctional compounds for controlling metal-mediated aggregation of the Aβ42 peptide. J. Am. Chem. Soc. 2012, 134, 6625-6636. 30. Hindo, S. S.; Mancino, A. M.; Braymer, J. J.; Liu, Y. H.; Vivekanandan, S.; Ramamoorthy, A.; Lim, M. H. Small molecule modulators of copper-induced Aβ aggregation. J. Am. Chem. Soc. 2009, 131, 16663-16665. 31. Choi J. S.; Braymer, J. J.; Nanga, R. P. R.; Ramamoorthy, A.; Lim, M. H. Design of small molecules that target metal-Aβ species and regulate metal-induced Aβ aggregation and neurotoxicity. Proc. Natl. Acad. Sci. USA 2010, 107, 21990-21995. 32. Choi J. S.; Braymer, J. J.; Park, S. K.; Mustafa, S.; Chae, J. H.; Lim, M. H. Synthesis and characterization of IMPY derivatives that regulate metal-induced amyloidal-β aggregation. Metallomics, 2011, 3, 284-291. 33. Hyman, B. T. Amyloid-dependent and Amyloid-independent stages of Alzheimer disease amyloidal-dependent and amyloidal-independent stages of Alzheimer disease. Arch. Neurol. 2011, 68, 1062-1064. 34. Inestrosa, N. C.; Alvarez, A.; Pe’rez, C. A.; Moreno, R. D.; Vicente, M.; Linker, C.; Casanueva, O. I.; Soto, C.; Garrido, J.; Acetylcholinesterase accelerates assembly of amyloidal-β peptides into Alzheimer’s fibrils: possible role of the peripheral site of the enzyme. Neuron, 1996, 16, 881-891. 35. Watkins, P. B.; Zimmerman, H. J.; Knapp, M. J.; Gracon, S. I.; Lewis, K. W. Hepatotoxic effects of tacrine administration in patients with Alzheimer’s disease. JAMA, J. Am. Med. Assoc. 1994, 271, 992-998. 36. Bartolini, M.; Bertucci, C.; Cavrini, V.; Andrisano, V. Beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. Biochem. Pharmacol. 2003, 65, 407-416. 37. Bolognesi, M. L.; Cavalli, A.; Valgimigli, L.; Bartolini, M.; Rosini, M.; Andrisano, V.; Recanatini, M.; Melchiorre, C. Multi-target-directed drug design strategy: From a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer’s disease. J. Med. Chem. 2007, 50, 6446-6449. 38. Minarini, A.; Milelli, A.; Tumiatti, V.; Rosini, M.; Simoni, E.; Bolognesi, M. L.; Andrisano, V.; Bartolini, M.; Motori, E.; Angeloni, C.; Hrelia, S. Cystamine-tacrine dimer: A new multi-target-directed ligand as potential therapeutic agent for Alzheimer’s disease treatment. Neuropharmacology, 2012, 62, 997-1003. 39. Camps, P.; Formosa, X.; Galdeano, C.; Munoz-Torrero, D.; Ramı’rez, L.; Gomez, E.; Isambert, N.; Lavilla, R.; Badia, A.; Clos, M. V.; Bartolini, M.; Mancini, F.; Andrisano, V.; Arce, M. P.; Rodrı’guez-Franco, M. I. ; Huertas, O.; Dafni, T.; Luque, F. J. Pyrano[3,2-c]quinoline-6-Chlorotacrine hybrids as a novel family of acetylcholinesterase and β-amyloidal-directed anti-Alzheimer compounds. J. Med. Chem. 2009, 52, 5365-5379. 40. Fernandez-Bachiller, M. I.; Perez, C.; Gonzalez-Munoz, G. C.; Conde, S.; Lopez, M. G.; Villarroya, M.; Garcı’a, A. G.; Rodrı’guez-Franco, M. I. Novel Tacrine-8-Hydroxyquinoline hybrids as multifunctional agents for the treatment of Alzheimer’s Disease, with neuroprotective, cholinergic, antioxidant, and copper-complexing properties. J. Med. Chem. 2010, 53, 4927-4937. 41. Huang, L.; Su, T.; Shan, W. J.; Luo, Z. H.; Sun, Y.; He, F.; Li, X. S. Inhibition of cholinesterase activity and amyloidal aggregation by berberine-phenylbenzoheterocyclic and tacrine-phenylbenzoheterocyclic hybrids. Bioorg. Med. Chem. 2012, 20, 3038-3048. 42. Pi, R. B.; Mao, X. X.; Chao, X. J.; Cheng, Z. Y.; Liu, M. F.; Duan, X. L.; Ye, M. Z.; Chen, X. H.; Mei, Z. R.; Liu, P. Q.; Li, W. M. Han, Y. F. Tacrine-6-Ferulic Acid, a novel multifunctional dimer, inhibits amyloidal-β-mediated Alzheimer’s disease associated pathogenesis in vitro and in vivo. PLos One. 2012, 7, e31921. 43. Galdeano, C.; Viayna, E.; Sola, I.; Formosa, X.; Camps, P.; Badia, A.; Clos, M. V.; Relat, J.; Ratia, M.; Bartolini, M.; Mancini, F.; Andrisano, V.; Salmona, M.; Minguillon, C.; Gonzalez-Munoz, G. C.; Rodriguez-Franco, M. I.; Bidon-Chanal, A.; Luque, F. J.; Munoz-Torrero, D. Huprine-Tacrine heterodimers as anti-amyloidogenic compounds of potential interest against Alzheimer’s and Prion diseases. J. Med. Chem. 2012, 55, 661-669. 44. Rizzo, S.; Bisi, A.; Bartolini, M.; Mancini, F.; Belluti, F.; Gobbi, S.; Andrisano, V.; Rampa, A. Multi-target strategy to address Alzheimer’s disease: Design, synthesis and biological evaluation of new tacrine-based dimmers. Eur. J. Med. Chem. 2011, 46, 4336-4343. 45. Zheng, W.; Li, J.; Qiu, Z.; Xia, Z.; Li, W.; Yu, L. N.; Chen, H. L.; Chen, J. X.; Chen, Y.; Hu, Z.; Zhou, W.; Shao, B. Y.; Cui, Y. Y.; Xie, Q.; Chen, H. Z. Novel bis-(−)-nor-meptazinol derivatives act as dual binding site AChE inhibitors with metal-complexing property. Toxicol. Appl. Pharmacol. 2012, 264, 65-72. 46. (a) Cavalli, A.; Bolognesi, M. L.; Capsoni, S.; Andrisano, V.; Bartolini, M.; Margotti, E.; Cattaneo, A.; Recanatini, M.; Melchiorre, C. A small molecule targeting the multifactorial nature of Alzheimer’s disease. Angew. Chem. Int. Ed. 2007, 46, 3689-3692; (b) Bolognesi, M. L.; Banzi, R.; Bartolini, M.; Cavalli, A.; Tarozzi, A.; Andrisano, V.; Minarini, A.; Rosini, M.; Tumiatti, V.; Bergamini,C.; Fato, R.; Lenaz, G.; Hrelia, P.; Cattaneo, A.; Recanatini, M.; Melchiorre, C. Novel class of quinone-bearing polyamines as Multi-target-directed ligands to combat Alzheimer’s disease. J. Med. Chem. 2007, 50, 4882-4897. 47. Montalcini, R. L. The nerve growth factor 35 years later. Science 1987, 237, 1154-1162. 48. Tuszynski, M. H.; Thal, L.; Pay, M.; Salmon, D. P.; U, H. S.; Roy Bakay, R.; Patel, P.; Blesch, A.; Vahlsing, H. L.; Ho, G.; Tong, G.; Potkin, S. G.; Fallon, J.; Hansen, L.; Mufson, E.J.; Kordower, J. H.; Gall, G.; Conner, J. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat. Med. 2005, 11, 551-555. 49. Porzner, M.; Muller, T.; Seufferlein, T. SR57746A/xaliproden, a non-peptide neurotrophic compound: prospects and constraints for the treatment of nervous system diseases. Expert Opin. Investig. Drugs 2009, 18, 1765-1772. 50. Hirata, K.; Yamaguchi, H.; Takamura, Y.; Takagi, A.; Fukushima, T.; Iwakami, N.; Saitoh, A.; Nakagawa, M.; Yamada, T. A novel neurotrophic agent, T-817MA [1-{3-[2-(1-Benzothiophen-5-yl) Ethoxy] Propyl}-3-azetidinol Maleate], attenuates amyloidal-β-induced neurotoxicity and promotes neurite outgrowth in rat cultured central nervous system neurons. J. Pharm. Exp. Ther. 2005, 314, 252-259. 51. Avramovich-Tirosh, Y.; Amit, T.; Bar-Am, O.; Zheng, H.; Fridki, M.; Youdim, M. B. H. Therapeutic targets and potential of the novel brain-permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer’s disease. J. Neurochem. 2007, 100, 490-502. 52. Weinreb, O.; Mandel, S.; Bar-Am, O.; Yogev-Falach, M.; Avramovich-Tirosh, Y.; Amit, T.; Youdim, M. B. H. Multifunctional Neuroprotective Derivatives of Rasagiline as Anti-Alzheimer’s Disease Drugs. Neurotherapeutics 2009, 6, 163-174. 53. Liu, Y. B.; Dargusch, R.; Maher, P.; Schubert, D. A broadly neuroprotective derivative of curcumin. J. Neurochem. 2008, 105, 1336-1345. 54. Chen, Q.; Prior, M.; Dargusch, R.; Roberts, A.; Riek, R.; Eichmann, C.; Chiruta, C.; Akaishi, T.; Abe, K.; Maher, P.; Schubert, D. A Novel neurotrophic drug for cognitive enhancement and Alzheimer’s disease. PLoS ONE 2011, 6, e27865. 2.6 References: 1. Borg, J.; Toazara, J.; Hietter, H.; Henry, M.; Schmitt, G.; Luu, B. Neurotrophic effect of naturally occurring long-chain fatty alcohols on cultured CNS neurons. FEBS Lett. 1987, 213, 406-410. 2. Luu, B.; Aguilar, J. G. D.; Girlanda-Junges, C. Cyclohexenonic long-chain fatty alcohols as neuronal growth stimulators. Molecules 2000, 5, 1439-1460. 3. Keyling-Bilger, F.; Schmitt, G.; Beck, A.; Luu, B. Synthesis of optically active diastereomers of a nonproteic neurotrophic mimetic. Tetrahedron 1996, 52, 14891-14904. 4. Coowar, D.; Bouissac, J.; Hanbali, M.; Paschaki, M.; Mohier, E.; Luu, B. Effects of indole fatty alcohols on the differentiation of neural stem cell derived neurospheres. J. Med. Chem. 2004, 47, 6270-6282. 5. Mazen Hanbali, M.; Bagnard, D.; Luu, B. Solid-phase synthesis of quinol fatty alcohols, design of N/O-substituted quinol fatty alcohols and comparative activities on axonal growth. Bioorg. Med. Chem. Lett. 2006, 16, 3917-3920. 6. Hauss, F.; Liu, J. W.; Michelucci, A.; Coowar, D.; Morga, E.; Heuschling, P.; Luu, B. Dual bioactivity of resveratrol fatty alcohols: differentiation of neural stem cells and modulation of neuroinflammation. Bioorg. Med. Chem. Lett. 2007, 17, 4218-4222. 7. Aoki, S.; Matusi, K.; Wei, H.; Murakami, N.; Kobayashi, M. Structure-activity relationship of neuritogenic spongean acetylene alcohols, lembehynes. Tetrahedron 2002, 58, 5417-5422. 8. Yun, H. D.; Chou, T. C.; Dong, G. J.; Tian, Y.; Li, Y. M.; Danishefsky, S. J.; Total synthesis as a resource in drug discovery: the first in vivo evaluation of panaxytriol and its derivatives. J. Org. Chem. 2005, 70, 10375-10380. 9. Schmidt, F.; Champy, P.; Se’on-Me’niel, B.; Franck, X.; Raisman-Vozari, R.; Figade`re, B. Chemicals possessing a neurotrophin-like activity on dopaminergic neurons in primary culture. PLoS ONE 2009, 4, e6215. 10. Schmidt, F.; Douaron, G. L.; Champy, P.; Amar, M.; Seon-Meniel, B.; Raisman-Vozari, R.; Figadere, B. Tryptamine-derived alkaloids from Annonaceae exerting neurotrophin-like properties on primary dopaminergic neurons. Bioorg. Med. Chem. 2010, 18, 5103-5113. 11. Borg, J. The neurotrophic factor, n-hexacosanol, reduces the neuronal damage induced by the neurotoxin, kainic acid. J. Neurosci. Res. 1991, 29, 2952-2967. 12. Hyman, B. T. Amyloid-dependent and amyloid-independent stages of Alzheimer disease. Arch. Neurol. 2011, 68, 1062-1064. 13. Cherny, R. A.; Atwood, C. S.; Xilinas, M. E.; Gray, D. N.; Jones, W. D.; McLean,C. A.; Barnham, K. J.; Volitakis, I.; W. Fraser, F. W.; Kim, Y. S.; Huang, X. D.; Goldstein, L. E.; Moir, R. D.; Lim, J. T.; Beyreuther, K.; Zheng, H.; Tanzi, R. E.; Masters, C. L.; Bush, A. I. Treatment with a copper-zinc chelator markedly and rapidly Inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001, 30, 665-676. 14. Tateishi, J.; Kuroda, S.; SMto, A.; Otsuki, S. Experimental myelo-optic neuropathy induced by Clioquinol. Acta neuropathol. 1973, 24, 304-320. 15. Benvenisti-Zarom, L.; Chen, J.; Regan, R. F. The oxidative neurotoxicity of clioquinol. Neuropharmacology 2005, 49, 687-694. 16. Asakura, K.; Ueda, A.; Kawamura, N.; Ueda, M.; Mihara, T.; Mutoh, T.; Clioquinol inhibits NGF-induced Trk autophosphorylation and neurite outgrowth in PC12 cells. Brain Res. 2009, 1301, 110-115. 17. Sampson, E. L.; Jenagaratnam, L.; McShane, R. Metal protein attenuating compounds for the treatment of Alzheimer’s disease. Cochrane Database Syst. Rev. 2008, 1, 1-13. 18. Adlard, P. A.; Cherny, R. A.; Finkelstein, D. I.; Gautier, E.; Robb, E.; Cortes, M.; Volitakis, I.; Liu, X.; Smith, J. P.; Perez, K.; Laughton, K.; Li, Q. X.; Charman, S. A.; Nicolazzo, J. A.; Wilkins, S.; 1,3 Karolina Deleva, K.; 1 Toni Lynch, T.; Gaik Kok, G.; Ritchie, C. W.; Tanzi, R. E.; Cappai, R.; Masters, C. L.; Barnham, K. J.; Bush, A. I. Rapid restoration of cognition in Alzheimer’s transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Aβ. Neuron 2008, 59, 43-55. 19. Talekar, R. S. Design, Synthesis and Biological Evaluation of Quinoline Analogues. PhD thesis, Natinal Taiwan University, 2006. 20. Zhang, H.; Wang, Q. L.; Jiang, Y. B. 8-Methoxyquinoline based turn-on metal fluoroionophores. Tetrahedron Lett. 2007, 48, 3959-3962 21. Prodi, L.; Montalti, M.; Zaccheroni, N.; Bradshaw, J. S.; Izatt, R. M.; Savageb, P. B. Characterization of 5-chloro-8-methoxyquinoline appended diaza-18-crown-6 as a chemosensor for cadmium. Tetrahedron Lett. 2001, 42, 2941-2944. 22. Chang, P. T.; Talekar, R. S.; Kung, F. L.; Chern, T. R.; Lai, S. Y.; Yu, C. W.; Deore, R. R.; Huang, C. W.; Lin, J. H.; Chen, C. S.; Liu, J. R.; Chen, G. S. & Chern, J. W. manuscript in preparation. 23. Caris, C.; Baret, P.; Pierre, J. L. Serratrice, G. Synthesis and NMR Study of Two Lipophilic Iron(Ill) Sequestering Agents Based on 8-Hydroxyquinoline; H-bonding and Conformational Changes. Tetrahedron 1996, 52, 4659-4672. 24. 8-Hydroxy quinoline derivatives. WO2004007461 25. Meanwell, N. A. Synopsis of some recent tactical application of bioisosteres in drug design. J. Med. Chem. 2011, 54, 2529-2591. 26. Chang, P. T.; Kung, F. L.; Talekar, R. S.; Chen, C. S.; Lai, S. Y.; Lee, H. Y.; Chern, J. W. An improved screening model to identify inhibitors targeting zinc-enhanced amyloid aggregation. Anal. Chem. 2009, 81, 6944-6951. 27. Su, Y.; Sun, C. M.; Chuang, H. H.; Chang, P. T. Studies on the cytotoxic mechanisms of ginkgetin in a human ovarian adenocarcinoma cell line. Naunyn-Schmiedebergs Arch Pharmacol. 2000, 362, 82-90. 28. Fiedler, H. Notiz uber die Verwendung von polyphosphorsaure bei der reaktion nach DOBNER-v. MILLER. J. fur Praktische Chemie 1961, 13, 86. 29. Gershon, H.; Mcneil, M. W. 5- and 7-substituted 2-methyl-8-quinolinols J. Heterocyclic Chem. 1972, 9, 659-667. 30. Ruetgerswerke. Chem. Abstr. 1972, 77, #151993. 31. Vaidya, M. G.; Cannon, J. G. Derivatives of 8-hydroxy-2-quinolineacrylic acid. II. J. Med. Chem. 1962, 5, 389-397. 32. Nickel, P.; Fink, E. 2-, 3- and 4-Mono-, di- und trimethylderivate von 6- (4-Diathylamino-l-methylbutylamino)-5,8-dimethoxychinolin. Liebigs Ann. Chem. 1976, 367-382. 33. Warner, V. D.; Must, J. D.; Turesky, S. S.; Soloway, B. Synthesis and in vitro evaluation of 8-hydroxyquinolines as dental plaque inhibitors. J. Pharm. Sci. 1975, 64, 1563-1566. 34. Rauckman, B. S.; Tidwell, M. Y.; Johnson, J. V.; Roth, B. 2,4-Diamino-5-benzylpyrimidines and analogues as antibacterial agents. 10. 2,4-Diamino-5-(6-quinolylmethy1)- and -[(tetrahydro-6-quinoly1)methyl] pyrimidine derivatives. Further specificity studies. J. Med. Chem. 1989, 32, 1927-1935. 35. Biichi, J.; Aebi, A.; Deflorinl, A.; Hurni, H. Synthese und pharmakologische Wirkung einiger thiosemicarbazone von 8-hydroxychinolin-derivaten. Helv. Chim. Acta 1956, 39, 1676-1680. 36. Kitamura, C.; Maeda, N.; Kamada, N.; Ouchi, M.; Yoneda, A. Synthesis of 2-(substituted methyl)quinolin-8-ols and their complexation with Sn(II). J. Chem. Soc., Perkin Trans. 1, 2000, 5, 781-785. 3.6 References 1. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliver. Rev. 1997, 23, 3-25. 2. Oprea T. I.; Davis, A.M.; Teague, S.J.; Leeson, P. D. Is there a difference between leads and drugs? A historical perspective. J. Chem. Inf. Model. 2001, 41, 1308-1315. 3. Leeson, P. D. and Springthorpe, B. The influence of drug-like concepts on decision making in medicinal chemistry. Nat. Rev. Drug. Discov. 2007, 6, 881-890. 4. Meanwell, N. A. Improving drug candidates by design: A focus on physicochemical properties as a means of improving compound disposition and safety. Chem. Res. Toxicol. 2011, 24, 1420-1456. 5. Price, D. A.; Blagg, J.; Jones, L.; Greene, N.; Wager, T.; Physicochemical drug properties associated with in vivo toxicological outcomes: a review. Expert Opin. Drug Metab. Toxicol. 2009, 5, 921-931. 6. Walters, W. P. Going further than Lipinski’s rule in drug design. Expert Opin. Drug Discov. 2012, 7, 99-107. 7. Wager, T. T., Chandrasekaran, R. Y., Hou, X., Troutman, M. D., Verhoest, P. R., Villalobos, A., and Will, Y. Defining desirable central nervous system drug space through alignment of molecular properties, in vitro ADME, and safety attributes. ACS Chem. Neurosci. 2010, 1, 420-434. 8. Pardridge, W. M. Alzheimer’s disease drug development and the problem of the blood-brain barrier. Alzheimers Dement. 2009, 5, 427-432. 9. Kerns, E. H; Li, D. Drug-like properties: concepts, structure design and methods from ADME to toxicity optimization. Wiley 2008. 10. http://www.molsoft.com/mprop/mprop.cgi 11. Veber, D. F.; Johnson, S. R.; Cheng, H. Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 2002, 45, 2615-2623. 12. Schmidt, F.; Douaron, G. L.; Champy, P.; Amar, M.; Seon-Meniel, B.; Raisman-Vozari, R.; Figadere, B. Tryptamine-derived alkaloids from Annonaceae exerting neurotrophin-like properties on primary dopaminergic neurons. Bioorg. Med. Chem. 2010, 18, 5103-5113. 13. Pajouhesh, H. and Lenz, G. R. Medicinal chemical properties of successful central Nervous System Drugs. NeuroRx. 2005, 2, 541-553. 14. Lakatos, A.; Zsigo, E.; Hollender, D.; Nagy, N. V.; Fulop, D.; Simon, D.; Bozso, Z.; Kiss, T.; Two pyridine derivatives as potential Cu(II) and Zn(II) chelators in therapy for Alzheimer’s disease. Dalton Trans., 2010, 39, 1302-1315. 15. Zheng, H. L.; Weiner, L. M.; Bar-Am, O.; Epsztejn, S.; Cabantchik, Z. I.; Warshawsky, A.; Youdimb, M. B. H.; Fridkin, M. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. Bioorg. Med. Chem. 2005, 13, 773-783. 16. Avramovich-Tirosh, Y.; Amit, T.; Bar-Am, O.; Zheng, H. L. Fridkin, M.; Youdim, M. B. H. Therapeutic targets and potential of the novel brain-permeable multifunctional iron chelator–monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer’s disease. J. Neurochem. 2007, 100, 490-502. 17. Amit, T.; Avramovich-Tirosh, Y.; Youdim, M. B. H.; Mandel, S. Targeting multiple Alzheimer’s disease etiologies with multimodal neuroprotective and neurorestorative iron chelators. FASEB J. 2008, 22, 1296-1305. 178 18. 8-Hydroxy quinoline derivatives. WO2004007461 19. Aisen, P. S.; Gauthier, S.; Vellas, B.; Briand, R.; Saumier, D.; Laurin, J.; Garceau, D. Alzhemed: A Potential Treatment for Alzheimers Disease. Curr. Alz. Res. 2007, 4, 473-478. 20. Su, Y.; Sun, C. M.; Chuang, H. H.; Chang, P. T. Studies on the cytotoxic mechanisms of ginkgetin in a human ovarian adenocarcinoma cell line. Naunyn-Schmiedebergs Arch Pharmacol. 2000, 362, 82-90. | - |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/15659 | - |
| dc.description.abstract | 本論文設計構想是以天然物小葉水蓑衣中所分離出的正二十六烷醇及具有螯合金屬離子能力而達到溶解類澱粉斑塊功能的氯碘羥喹作為先導化合物並融合二者成為8-羥基喹啉-2-烷基醇衍生物作為目標化合物。以2-胺基酚在酸性條件下進行環化合成8-羥基喹啉，並以苄基化對羥基進行保護。接著在二位連接烷基醇及移除保護基便得到目標化合物5。同時以之前實驗室化合物J2326 的研究為基礎，設計及合成一系列8-烷氧基喹啉-2-烷基醇衍生物。其生物活性測試結果證實確可減少類澱粉蛋白的聚集、誘發神經軸突生長以及促進神經細胞增生。除此之外，目標化合物對細胞無毒性以及在類澱粉蛋白所誘發神經退化的老鼠實驗中可改善其記憶。綜合以上所述，以化合物23o、23p、27i 及33i 最具有潛力並可作為未來進一步研究所需之試劑。
由於8-烷氧基喹啉-2-烷基醇衍生物溶解度普遍不佳且與鋅離子的作用力比8-羥基喹啉-2-烷基醇弱，本論文嘗試於喹啉環上2 位導入含氮原子的神經滋養功能基團替代長鏈烷基醇來改善性質。將喹啉環二位的甲基進行氧化成醛後再進行還原性胺化及可得到目標化合物。雖然其結果顯示僅有少數化合物在減少類澱粉蛋白聚集以及活化神經滋養效果與J2326 相仿，但其溶解度確實大幅改善並可提供更大的彈性以利未來的優化。總結來說，本論文開發出新穎羥烷基取代八羥基/烷氧基喹啉衍生物做為多效性神經滋養試劑的策略將來或許可應用於治療因蛋白質缺陷及堆積所造成的退化性神經疾病如阿茲海默症，帕金森氏症，杭丁頓舞蹈症及肌萎縮性側索硬化症。 | zh_TW |
| dc.description.abstract | 8-Hydroxyquinolin-2-ylalkyl alcohol derivatives were designed by merging two leads, hexacosanol which was isolated from natural plant Hygrophilia erecta Hochr
(Acanthaceae) and clioquinol which possessed metal chelation ability to dissolve fAβ as target compounds in this dissertation. 2-Aminophenol was cyclized under acidic condition to afford 8-hydroxyquinoline and the hydroxyl group was protected by benzylation. Subsequently, alkyl alcohol was introduced to C2 position and removal of protecting group to obtain target compound 5. Meanwhile, on the basis of previous study of J2326, a series of 8alkoxyquinolin-2-ylalkyl alcohol derivatives were designed and synthesized. The biological evaluation demonstrated that these compounds definitely reduce formation of Aβ aggregates, induce neurite outgrowth and stimulate neuron proliferation. Further, target compounds are nontoxic to the cells and improve the memory of fAβ-lesioned mice with neuron degeneration. In summary, compounds 23o, 23p, 27i and 33i are the most promising and serve as potential agents for further investigation in the future. Since poor solubility and weaker interaction with zinc ions of 8-alkoxyquinolin-2-ylalkyl alcohol derivatives were observed in comparison with 8-hydroxyquinolin-2-ylalkyl alcohol derivatives, neurotrophic functional moieties with nitrogen atom were introduced onto C2-position of quinoline ring to replace alkyl alcohols for the purpose of improving the properties. Methyl group on C2-position of quinoline ring was oxidized to aldehyde and subsequently reductive amination to afford target compounds. Although very few compounds are comparable to J2326 in anti-fAβ and activation of neurotrophic activities, solubility was definitely improved to provide more flexibility for compound optimization in the future. In conclusion, the strategy in the development of novel hydroxyalkyl substituted 8hydroxyl/alkoxyquinolines as multifunctional neurotrophic agents might be applied to other neurodegenerative diseases treatments with aberrant proteins aggregation such as Alzheimer, Parkinson, Huntington diseases and Amyotrophic lateral sclerosis. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-07T17:49:34Z (GMT). No. of bitstreams: 1
ntu-102-F95423025-1.pdf: 14504620 bytes, checksum: 52cb3df50ccc6a222e6a898ae0cb664a (MD5) Previous issue date: 2013 | en |
| dc.description.tableofcontents | 中文摘要...................................................i
Abstract..................................................ii List of Schemes...........................................v List of Tables..................................vi List of Figures..................................vii List of Abbreviation...................................viii Chapter 1 Introduction 1.1 Background of neurodegenerative diseases..............1 1.2 Epidemiology and healthcare of AD................2 1.3 Drug development strategies for anti-Alzheimer’s therapy............................3 1.4 Summary.......................................16 1.5 References………………………………………………………………...17 Chapter 2 Design and Synthesis of Quinolin-2-ylalkyl Alcohols 2.1 Introduction and Design.................................................................................25 2.2 Synthetic results.............................................................................................29 2.3 Biological activities and discussion...............................................................35 2.4 Summary…....................................................................................................49 2.5 Experimental section……………………………………………………….50 2.6 References…………………………………………………………………139 Chapter 3 Solubility Improvement for Optimization of Quinolin-2-ylalkyl Alcohols 3.1 Introduction and Design...............................................................................144 3.2 Synthetic results...........................................................................................148 3.3 Biological activities and discussion.............................................................150 3.4 Summary......................................................................................................155 3.5 Experimental section….……………………………………………….....….156 3.6 References…….…………………………………………….……………….176 Conclusions......................................179 | - |
| dc.language.iso | en | - |
| dc.subject | 喹 | zh_TW |
| dc.subject | 啉 | zh_TW |
| dc.subject | 阿茲海默症 | zh_TW |
| dc.subject | quinoline | en |
| dc.title | 設計合成具有多重功效之羥烷基取代八羥基/烷氧基喹啉衍生物作為治療阿茲海默症之活性評估 | zh_TW |
| dc.title | Design, Synthesis and Biological Evaluation of Hydroxyalkyl Substituted 8-Hydroxyl/Alkoxyquinolines with Multifunctional Activities against Alzheimer’s Disease | en |
| dc.type | Thesis | - |
| dc.date.schoolyear | 101-1 | - |
| dc.description.degree | 博士 | - |
| dc.contributor.oralexamcommittee | 王光昭,尤啟冬,顧記華,陳香惠,孔繁璐 | - |
| dc.subject.keyword | 喹,啉,阿茲海默症, | zh_TW |
| dc.subject.keyword | quinoline, | en |
| dc.relation.page | 180 | - |
| dc.rights.note | 未授權 | - |
| dc.date.accepted | 2013-01-31 | - |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 藥學研究所 | zh_TW |
| 顯示於系所單位： | 藥學系 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-102-1.pdf 未授權公開取用 | 14.16 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。